Pre-made Lacnotuzumab benchmark antibody ( Whole mAb, anti-CSF1 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-289
Anti-CSF1 therapeutic antibody (Pre-made Lacnotuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lacnotuzumab, as known as MCS110, is a novel, high-affinity, humanized, anti-CSF-1 monoclonal antibody that prevents CSF-1 from activating the CSF-1R. The drug is being developed by Novartis Europharm Limited.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CSF1 therapeutic antibody (Pre-made Lacnotuzumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Seoul National University Hospital|
|Conditions Active||Breast cancer;Gastric cancer;Giant cell tumour of tendon sheath;Pigmented villonodular synovitis;Malignant melanoma;Solid tumours|
|Conditions Discontinued||Bone metastases;Prostate cancer|